Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB)

Authors
Category Primary study
JournalJournal of Hepatology
Year 2022
This article has no abstract
Epistemonikos ID: d1fb5b1aa0dda91aa0980f6f7b072a53c8effe50
First added on: Feb 14, 2025